Stockscreener 앱 받기
4.72
3.51%
0.16
시간 외 거래:
4.72
전일 마감가:
$4.56
열려 있는:
$4.6
하루 거래량:
176.24K
Relative Volume:
0.91
시가총액:
$266.92M
수익:
$34.16M
순이익/손실:
$-98.43M
주가수익비율:
-2.0171
EPS:
-2.34
순현금흐름:
$-119.33M
1주 성능:
-5.98%
1개월 성능:
+15.97%
6개월 성능:
+14.01%
1년 성능:
-40.25%
1일 변동 폭
$4.40
$4.76
1주일 범위
$4.40
$5.255
52주 변동 폭
$2.9448
$8.445
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.72 | 257.87M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 재개 | B. Riley Securities | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Foghorn Therapeutics CEO joins Evercore Healthcare Conference - Traders Union
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Foghorn Therapeutics (Nasdaq: FHTX) to Join 8th Evercore Healthcare Conference - Stock Titan
Why Foghorn Therapeutics Inc. stock is a must watch in 2025Quarterly Performance Summary & Fast Moving Market Watchlists - newser.com
Can Foghorn Therapeutics Inc. stock maintain growth trajectory2025 Performance Recap & Risk Controlled Daily Plans - newser.com
How Foghorn Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Market Pulse Alerts - newser.com
How Foghorn Therapeutics Inc. stock valuations compare to rivalsQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Is Foghorn Therapeutics Inc. stock safe for conservative investorsQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Is Foghorn Therapeutics Inc. stock bottoming outShare Buyback & Fast Gain Stock Tips - newser.com
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect? - Zacks Investment Research
FHTX: SMARCA2 program advances with Lilly partnership; multiple novel assets near IND and strong funding - TradingView
Identifying reversal signals in Foghorn Therapeutics Inc.July 2025 Action & AI Enhanced Trading Signals - newser.com
How Foghorn Therapeutics Inc. stock compares to growth peers2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Check Out Foghorn Therapeutics Inc (FHTX)’s Trade Data Rather Than the Analysts’ Views - Setenews
4DMT Appoints Kristian Humer as Chief Financial Officer - GlobeNewswire Inc.
Applying big data sentiment scoring on Foghorn Therapeutics Inc.Trade Ideas & Real-Time Chart Breakout Alerts - newser.com
Why Foghorn Therapeutics Inc. stock could outperform in 2025July 2025 Weekly Recap & Capital Efficiency Focused Ideas - newser.com
How risky is Foghorn Therapeutics Inc. stock now2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Published on: 2025-11-15 18:34:42 - newser.com
Volatility clustering patterns for Foghorn Therapeutics Inc.July 2025 Trade Ideas & Free Technical Confirmation Trade Alerts - newser.com
Will Foghorn Therapeutics Inc. stock maintain growth story2025 Technical Overview & Weekly Consistent Profit Watchlists - Fundação Cultural do Pará
Foghorn Therapeutics Unveils Strategic Advancements with Lilly - MSN
Momentum divergence signals in Foghorn Therapeutics Inc. chartJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):